About 10 results found for searched term "61-38-1" (0.119 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3123 | Vorapaxar | PAR |
| SCH 530348 | ||
| Vorapaxar (SCH 530348) is a potent and orally active thrombin receptor (PAR-1) antagonist with Ki of 8.1 nM. | ||
| M4551 | Trigonelline hydrochloride | Anti-infection |
| Trigonelline chloride | ||
| Trigonelline chloride is an alkaloid with potential antidiabetic activity that can be isolated from Trigonella foenum-graecum L or Leonurus artemisia. Trigonelline chloride is a potent Nrf2 inhibitor that blocks Nrf2-dependent proteasome activity, thereby enhancing apoptosis in pancreatic cancer cells. | ||
| M20352 | WAY-270252 | IGF-1R |
| WAY-270252 is a IGF-1R/SRC inhibitor. | ||
| M28692 | Bezuclastinib | c-Kit |
| CGT9486; PLX 9486 | ||
| Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001 < IC50 < 1 μM). Bezuclastinib is a tyrosine kinase inhibitor. | ||
| M5873 | Pexmetinib (ARRY-614) | p38 MAPK |
| ARRY-614 | ||
| Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1. | ||
| M11405 | Inavolisib (GDC-0077) | PI3K |
| GDC-0077; RG6114；RO-7113755 | ||
| Inavolisib (GDC-0077; RG6114) is a potential best-in-class, orally selective PI3Kα inhibitor (IC50=0.038 nM). GDC-0077 (RG6114) exerts its activity by binding to the ATP binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. GDC-0077 (RG6114) is more selective for mutants compared to wild-type PI3Kα. It can trigger the degradation of mutation-producing PIK3α. | ||
| M13605 | AUZ 454 | CDK |
| K03861 | ||
| AUZ 454 (K03861) is a type II CDK2 inhibitor with Kd of 8.2 nM. AUZ 454 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins. | ||
| M28043 | ITX5061 | p38 MAPK |
| ITX5061 is a type II inhibitor of p38 MAPK and also an antagonist of scavenger receptor B1 (SR-B1). | ||
| M28716 | ML380 | AChR/AChE |
| ML380 is a potent, subtype-selective, and brain-penetrant positive allosteric modulator (PAM) of M5 mAChR, with EC50s of 190 and 610 nM for human and rat M5, respectively. ML380 exhibits moderate selectivity versus the M1 and M3 mAChR subtypes. ML380 could increase the affinity of ACh for the M5 mAChR. | ||
| M39017 | Emodic acid | p38 MAPK |
| Emodic acid (NSC624610) inhibits the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, ERK and JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of VEGF and MMP. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
